Display options
Cite
Shin SY, Kim CG, Jung YJ, et al. The UPR inducer DPP23 inhibits the metastatic potential of MDA-MB-231 human breast cancer cells by targeting the Akt-IKK-NF-κB-MMP-9 axis. Sci Rep. 2016;6:34134doi: 10.1038/srep34134.
Shin, S. Y., Kim, C. G., Jung, Y. J., Lim, Y., & Lee, Y. H. (2016). The UPR inducer DPP23 inhibits the metastatic potential of MDA-MB-231 human breast cancer cells by targeting the Akt-IKK-NF-κB-MMP-9 axis. Scientific reports, 634134. https://doi.org/10.1038/srep34134
Shin, Soon Young, et al. "The UPR inducer DPP23 inhibits the metastatic potential of MDA-MB-231 human breast cancer cells by targeting the Akt-IKK-NF-κB-MMP-9 axis." Scientific reports vol. 6 (2016): 34134. doi: https://doi.org/10.1038/srep34134
Shin SY, Kim CG, Jung YJ, Lim Y, Lee YH. The UPR inducer DPP23 inhibits the metastatic potential of MDA-MB-231 human breast cancer cells by targeting the Akt-IKK-NF-κB-MMP-9 axis. Sci Rep. 2016 Sep 23;6:34134. doi: 10.1038/srep34134. PMID: 27658723; PMCID: PMC5034246.
Copy Download .nbib Format: NLM
Share it on

Sci Rep. 2016 Sep 23;6:34134. doi: 10.1038/srep34134.

The UPR inducer DPP23 inhibits the metastatic potential of MDA-MB-231 human breast cancer cells by targeting the Akt-IKK-NF-κB-MMP-9 axis.

Scientific reports

Soon Young Shin, Chang Gun Kim, You Jung Jung, Yoongho Lim, Young Han Lee

Affiliations

  1. Department of Biological Sciences, College of Biological Science and Biotechnology, Konkuk University, Seoul 05029, Republic of Korea.
  2. Cancer and Metabolism Institute, Konkuk University, Seoul 05029, Republic of Korea.
  3. Division of Bioscience and Biotechnology, College of Biological Science and Biotechnology, BMIC, Konkuk University, Seoul 05029, Republic of Korea.

PMID: 27658723 PMCID: PMC5034246 DOI: 10.1038/srep34134

Abstract

(E)-3-(3,5-dimethoxyphenyl)-1-(2-methoxyphenyl)prop-2-en-1-one (DPP23) is a synthetic polyphenol derivative that selectively induces apoptosis in cancer cells through the unfolded protein response pathway. In the present study, we evaluated the effect of DPP23 on tumour invasion and metastasis. Here, we show that DPP23 inhibited tumour necrosis factor alpha (TNFα)-induced motility, F-actin formation, and the invasive capability of MDA-MB-231 cells. DPP23 inhibited NF-κB-dependent MMP-9 expression at the transcriptional level. Akt is involved in the activation of IKK, an upstream regulator of NF-κB. DPP23 inhibited IKK and Akt, and knockdown of Akt2 significantly inhibited TNFα-induced IKK phosphorylation. We found that DPP23 bound to the catalytic domain of Akt2, as revealed by an in silico molecular docking analysis. These results suggest that DPP23 prevents TNFα-induced invasion of highly metastatic MDA-MB-231 breast cancer cells by inhibiting Akt-IKK-NF-κB axis-mediated MMP-9 gene expression. In addition, DPP23 attenuated experimental liver metastasis in a syngenic intrasplenic transplantation model using 4T1 mouse mammary carcinoma cells. Collectively, these results suggest that DPP23 could be used as a potential platform for the prevention of invasion and metastasis of early-stage breast cancer or as an adjuvant for chemo/radiotherapy.

References

  1. Nature. 2010 Jan 28;463(7280):485-92 - PubMed
  2. Nat Rev Cancer. 2009 Apr;9(4):239-52 - PubMed
  3. Oncogene. 1993 Feb;8(2):395-405 - PubMed
  4. J Biol Chem. 1999 Jul 30;274(31):21528-32 - PubMed
  5. Evid Based Complement Alternat Med. 2013;2013:815621 - PubMed
  6. Bioorg Med Chem. 2014 Mar 15;22(6):1809-20 - PubMed
  7. Cancer Lett. 2016 Mar 1;372(1):1-9 - PubMed
  8. Mol Cancer Res. 2010 Apr;8(4):507-19 - PubMed
  9. J Biol Chem. 2010 Oct 1;285(40):30731-40 - PubMed
  10. J Med Chem. 2008 Sep 25;51(18):5663-79 - PubMed
  11. J Natl Cancer Inst. 1986 Aug;77(2):311-6 - PubMed
  12. J Natl Cancer Inst. 1986 Dec;77(6):1303-8 - PubMed
  13. Cell. 2000 Jan 7;100(1):57-70 - PubMed
  14. Int J Oncol. 1999 Feb;14(2):291-300 - PubMed
  15. Bioorg Med Chem. 2013 Jul 15;21(14):4250-8 - PubMed
  16. Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):10983-5 - PubMed
  17. Oncogene. 1999 Nov 22;18(49):6853-66 - PubMed
  18. Food Chem Toxicol. 2011 Aug;49(8):1745-52 - PubMed
  19. Int Immunopharmacol. 2011 Mar;11(3):295-309 - PubMed
  20. Bioorg Med Chem Lett. 2015 Jan 1;25(1):128-32 - PubMed
  21. Biochim Biophys Acta. 2013 Oct;1829(10):1066-74 - PubMed
  22. Nat Rev Cancer. 2009 May;9(5):361-71 - PubMed
  23. Genes Dev. 2008 Jun 1;22(11):1490-500 - PubMed
  24. Curr Opin Cell Biol. 2009 Apr;21(2):256-61 - PubMed
  25. Crit Rev Biochem Mol Biol. 2002 Dec;37(6):375-536 - PubMed
  26. Nat Rev Cancer. 2002 Mar;2(3):161-74 - PubMed
  27. Cancer Res. 1992 Mar 15;52(6):1399-405 - PubMed
  28. Cell. 2007 Jun 29;129(7):1261-74 - PubMed
  29. Cancer Res. 1998 Apr 1;58(7):1486-93 - PubMed
  30. J Clin Invest. 2009 Jun;119(6):1429-37 - PubMed
  31. Cancer Res. 2006 Apr 15;66(8):3963-6 - PubMed
  32. Clin Cancer Res. 2014 Aug 15;20(16):4302-13 - PubMed
  33. Mol Cancer. 2013 Aug 02;12:86 - PubMed
  34. Cancer Res. 2003 Jan 1;63(1):196-206 - PubMed
  35. Neuropharmacology. 2008 Oct;55(5):819-25 - PubMed
  36. Toxicol Appl Pharmacol. 2008 Jun 15;229(3):386-98 - PubMed
  37. J Immunol. 2004 Oct 15;173(8):5196-208 - PubMed
  38. Eur J Med Chem. 2015 Jun 15;98:69-114 - PubMed
  39. Infect Immun. 2003 Aug;71(8):4414-20 - PubMed
  40. J Agric Food Chem. 2013 Dec 26;61(51):12588-97 - PubMed
  41. Nature. 2008 Jul 24;454(7203):436-44 - PubMed
  42. Genes Nutr. 2011 May;6(2):125-47 - PubMed
  43. Cancer Res. 2009 Jun 15;69(12):5057-64 - PubMed
  44. Mol Cell Biol. 1999 Jul;19(7):4798-805 - PubMed
  45. Protein Eng. 1995 Feb;8(2):127-34 - PubMed
  46. Mol Cell Biol. 2001 Mar;21(6):2203-12 - PubMed

Publication Types